This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 January - 6 February 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, Bacillus cereus toxin in infant formula, mass gathering monitoring, mpox, nipah virus, and Middle East respiratory virus syndrome.
Respiratory virus circulation is elevated across the EU/EEA. The circulation of influenza viruses remains high with early signs of a new increase, RSV circulation is elevated and increasing, and SARS-CoV-2 circulation remains at low levels.
ECDC cooperates with international partners, such as the World Health Organization and the centres for disease control and prevention (CDCs) across the globe.
This list below shows the current accommodation sites in EU/EEA countries with which clusters of Legionnaires’ disease have been identified but where the European Legionnaires’ disease Surveillance Network (ELDSNet) is unable to assess the risk of Legionella infection, or where ELDSNet believe there may be increased risk to travellers.
During their two-year fellowship, ECDC Fellowship Programme fellows are placed in different training sites.
Training sites selected to host a fellow are those with responsibilities for communicable disease surveillance, epidemiology, and public health advice. Selection criteria include an assessment of the training site’s potential for the practice of intervention epidemiology or public health microbiology and the quality of training supervision available for the fellows.
The purpose of the Audit Committee is to assist the Management Board in fulfilling its oversight responsibilities for the financial reporting process, the system of internal control and the audit process.
